Sentences with phrase «lung cancer patients at»

The drug is given to a subset of lung cancer patients at a daily dose of 150 mg, but whether this dosing strategy was the best way to prolong survival had not been empirically tested.

Immune cells modified by CRISPR - Cas9 were inserted into a lung cancer patient at the West China Hospital in Chengdu in the hopes that they'll be able to fight tumors, and 10 people total will receive injections of CRISPR re-engineered cells in order to assess the method's safety.

Not exact matches

Researchers from the Sichuan University in Chengdu inserted the re-engineered cells into a lung cancer patient participating in a clinical trial at the West China Hospital on October 28th, according to Nature.

The PD - 1 checkpoint inhibitor Keytruda hit its goals in a new trial in previously untreated non-small cell lung cancer patients, beating chemo at staving off cancer progression and extending patients» lives.

She spoke at Genentech, a cancer research firm, exchanged e-mails with half a dozen other cancer patients nationwide and was interviewed on NPR as a voice of nonsmoker lung - cancer sufferers.

Geoff Oxnard, an assistant professor of medicine at Dana - Farber Cancer Institute and Harvard Medical School in Boston and one of Paweletz's collaborators, remarks that «I had a hospitalized patient last week, she's sick with metastatic lung cancer, and she's exactly the kind of patient who might have an [epithelial growth factor receptor (EGFR)-RSB- mutation, but I simply didn't have enough tissue to ask those questions yet.&Cancer Institute and Harvard Medical School in Boston and one of Paweletz's collaborators, remarks that «I had a hospitalized patient last week, she's sick with metastatic lung cancer, and she's exactly the kind of patient who might have an [epithelial growth factor receptor (EGFR)-RSB- mutation, but I simply didn't have enough tissue to ask those questions yet.&cancer, and she's exactly the kind of patient who might have an [epithelial growth factor receptor (EGFR)-RSB- mutation, but I simply didn't have enough tissue to ask those questions yet.»

Urbanic said the overall findings of the study suggest that there are some patients with recurrent lung cancers who can be treated with another definitive course of radiation therapy and still have a chance at a cure.

Along the same lines, Daniel Sessler, an anesthesiologist at Cleveland Clinic in Ohio, is leading two randomized trials looking at whether nerve blocks added to general anesthesia reduce metastases in patients undergoing surgery to remove either breast or lung cancer.

«One of the toughest challenges of lung cancer is what to do for patients when the cancer comes back in an area that's been treated previously with radiation treatment,» said James J. Urbanic, M.D., lead author of the studies and a radiation oncologist at Wake Forest Baptist.

Chest imaging may be useful in diagnosing asthma in certain situations, including when the patient has a medically important smoking history or occupational chemical exposure, has long standing disease or mat be at risk for chronic obstructive lung disease or lung cancer.

A lung cancer specialist, Wrangle said 75 percent of lung cancer patients unfortunately are diagnosed at an incurable stage.

Dr. Glen Weiss, M.D., M.B.A., is the first author of the study abstract: Phase Ib / II Study of Pembrolizumab plus Chemotherapy in Advanced Cancer: Results of lung cancer patients receiving (at least) 1 prior line of thCancer: Results of lung cancer patients receiving (at least) 1 prior line of thcancer patients receiving (at least) 1 prior line of therapy.

Findings were presented at the WCLC are based on the updated results of 12 lung cancer patients enrolled in the clinical trial with pembro and irinotecan or gemcitabine with or without vinorelbine or docetaxel.

Immunotherapy with a live bacterium combined with chemotherapy demonstrated more than 90 % disease control and 59 % response rate in patients with malignant pleural mesothelioma (MPM), according to the results of a phase Ib trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.1

Because esophageal cancers can spread to the liver, lungs, bones and brain, the prognosis for patients diagnosed at late stages is poor.

An analysis of nearly 273,000 patients showed that between 2013 and 2014 there was a 1 % increase in the percentage of breast, lung, and colorectal cancers diagnosed at the earliest, most treatable stage.

A drug approved by the Food and Drug Administration (FDA) for melanoma in combination with a common cholesterol - lowering drug may show promise in controlling cancer growth in patients with non-small cell lung cancer (NSCLC), according to new research from the Icahn School of Medicine at Mount Sinai.

Phase I / II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.

Many lung cancer trials have traditionally excluded patients with brain metastases at baseline, expecting that the presence of metastases would create negative results that could in turn create the appearance of drug failure.

Combining radiation therapy with chemotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC) may curb disease progression dramatically when compared to NSCLC patients who only receive chemotherapy, according to a new randomized phase II clinical trial reported today at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD - L1 expression, according to the results of the phase III KEYNOTE - 024 trial presented at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine.

Patients with epidermal growth factor receptor (EGFR) expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerllung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzecancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, SwitzerlLung Cancer Conference (ELCC) 2016 in Geneva, SwitzeCancer Conference (ELCC) 2016 in Geneva, Switzerland.

Commenting on the findings, Prof Robert Pirker, programme director for lung cancer at the Vienna General Hospital in Vienna, Austria, not involved in the study, said: «This subgroup analysis shows that the effect of necitumumab was slightly greater in patients with EGFR expressing tumours than it was in the entire SQUIRE population.

Trinh and his colleagues used Surveillance, Epidemiology, and End Results Program (SEER) data to look at more than 2.5 million Asian American patients who were diagnosed with lung, breast, prostate or colorectal cancer (the three leading causes of cancer - related mortality within each gender) between 1991 and 2007.

«If you look at a set of lung cancer patients, like we did in the paper, who develop brain metastases, they all have those two genes in their primary lung cancer,» said Sheila Singh, the study's supervisor, associate professor at the Michael G. DeGroote School of Medicine, scientist with the Stem Cell and Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hoscancer patients, like we did in the paper, who develop brain metastases, they all have those two genes in their primary lung cancer,» said Sheila Singh, the study's supervisor, associate professor at the Michael G. DeGroote School of Medicine, scientist with the Stem Cell and Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hoscancer,» said Sheila Singh, the study's supervisor, associate professor at the Michael G. DeGroote School of Medicine, scientist with the Stem Cell and Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's HosCancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hospital.

In this study, researchers compared the effectiveness of the immunotherapy drug nivolumab (pronounced «nye VOL ue mab,» marketed at Opdivo), with standard - of - care chemotherapy in 541 patients with previously untreated or recurrent non-small cell lung cancer (NSCLC) that expressed PDL - 1 antibodies.

Principal Investigator John Morris, MD, clinical co-leader of the Molecular Therapeutics and Diagnosis Program for the CCC, co-leader of the UC Cancer Institute's Comprehensive Lung Cancer Program, professor in the division of hematology oncology at the UC College of Medicine and UC Health medical oncologist, says a number of antitumor vaccines have shown promise for causing immune responses against tumor antigens to improve patient outcomes.

Ceritinib provides longer progression - free survival than chemotherapy in crizotinib - pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement, according to results of the phase III ASCEND - 5 study presented at the ESMO 2016 Congress in Copenhagen.

Partnering with the U.S. Food and Drug Administration allowed Doebele and colleagues to access clinical trial data describing initial tumor response, PFS and OS for 305 patients with stage IIIb or IV non-small cell lung cancer on trials of ALK inhibitors and 355 similar patients on trials of immunotherapies directed at PD - 1.

This shows promise for breast cancer patients as diagnosing and treating the breast cancer at early stages means there is a greater chance of preventing cancer cells spreading to other tissues, such as the lungs, brain and bone.

«We now know much more about metabolic reprogramming of cancerous tissues in human patients, particularly that the activation of pyruvate carboxylase is important to lung cancer cell growth and survival,» said Fan, UK professor of toxicology and faculty member of the Markey Cancer Center and CESB at the University of Kencancer cell growth and survival,» said Fan, UK professor of toxicology and faculty member of the Markey Cancer Center and CESB at the University of KenCancer Center and CESB at the University of Kentucky.

«The prevalence of comorbidities is higher in older lung cancer patients than patients who are younger,» said K.M. Monirul Islam, M.D., Ph.D., an assistant professor in the department of epidemiology at the University of Nebraska Medical Center College of Public Health.

«As the population of the United States ages, there will be a higher number of lung cancer patients with comorbidities at diagnosis.»

When William Pao was a medical oncology fellow at Memorial Sloan Kettering Cancer Center (MSKCC) during the early 2000s, treating patients with metastatic non-small cell lung cancer (NSCLC) was rote: Every patient received the same chemotherapy reCancer Center (MSKCC) during the early 2000s, treating patients with metastatic non-small cell lung cancer (NSCLC) was rote: Every patient received the same chemotherapy recancer (NSCLC) was rote: Every patient received the same chemotherapy regimen.

The authors found that most lung cancer patients (regardless of stage) want physical activity advice directly from a physician at a cancer center before cancer treatment and exercise guidance may increase compliance with a dedicated program.

In a letter published in the cancer journal Annals of Oncology, researchers led by Professor Jean - Philippe Spano, head of the medical oncology department at Pitie - Salpetriere Hospital AP - HP in Paris, France, report that while treating an HIV - infected lung cancer patient with the cancer drug nivolumab, they observed a «drastic and persistent decrease» in the reservoirs of cells in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therapy.

The four - year study involved 461 patients at 24 medical oncology clinics at Princess Margaret Cancer Centre, University Health Network (UHN) with advanced lung, gastrointestinal, genitourinary, breast and gynecologic cancers.

To investigate why checkpoint inhibitors so often stop working, Velculescu; Valsamo Anagnostou, M.D., Ph.D., instructor of oncology at the Johns Hopkins University School of Medicine; Kellie N. Smith, Ph.D., a cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-CTLA4.

Professor Jean - Charles Soria, Chairman of the Drug Development Department at Gustave Roussy Cancer campus, France, will tell the Symposium: «Currently, there are no approved targeted therapies for mutant EGFR lung cancer patients who develop the T790M mutation, which means their disease inevitably will get Cancer campus, France, will tell the Symposium: «Currently, there are no approved targeted therapies for mutant EGFR lung cancer patients who develop the T790M mutation, which means their disease inevitably will get cancer patients who develop the T790M mutation, which means their disease inevitably will get worse.

Researchers analyzed 3,640,229 patients in the Surveillance, Epidemiology, and End Results (SEER) database and looked at suicide deaths for all cancers and for lung, prostate, breast and colorectal cancers individually.

A lung cancer diagnosis appears to put patients at the greatest risk of suicide when compared to the most common types of non-skin cancers, according to new research presented at the ATS 2017 International Conference.

In a study of 124 patients with advanced breast, lung, and prostate cancers, a new, high - intensity genomic sequencing approach detected circulating tumor DNA at a high rate.

Susan Galbraith, head of the oncology innovative medicines unit at AstraZeneca, said: «Lung cancer is still the leading cancer killer, and we are working on a number of potential treatment options that could provide patients with a better chance of beating the disease.

By December 2007 Shaw had joined the clinical team testing Xalkori at Mass General and soon enrolled her first few ALK - positive lung cancer patients.

Alice Shaw recalls a signal moment in 2004 — just as she was finishing her oncology fellowship at MIT — when scientists discovered that mutations in a gene for epidermal growth factor receptor (EGFR) were the culprits in about 10 to 15 percent of lung cancer patients.

The results published in the October issue of the Journal of Thoracic Oncology, the official journal for the International Association for the Study of Lung Cancer, show that TNI levels were undetectable in all patients before RT and increased slightly in 2 patients following RT but these returned to undetectable levels at the first follow - up.

«We wanted to look at the patients» tumor and immune system prior to treatment and examine it again after treatment for changes,» said Patrick Forde, first author and co-principle investigator of the trial and a lung cancer oncologist in the Bloomberg ~ Kimmel Institute of Cancer Immunothcancer oncologist in the Bloomberg ~ Kimmel Institute of Cancer ImmunothCancer Immunotherapy.

Nicolas Faris, MDiv and Raymond Osarogiagbon, MBBS led a group of researchers from Baptist Cancer Center and the University of Memphis in Tennessee, who reviewed hospital records for all patients who underwent surgery for suspected lung cancer at Baptist Memorial Hospital between January 2009 and JuneCancer Center and the University of Memphis in Tennessee, who reviewed hospital records for all patients who underwent surgery for suspected lung cancer at Baptist Memorial Hospital between January 2009 and Junecancer at Baptist Memorial Hospital between January 2009 and June 2013.

The Lung Cancer Mutation Consortium at the University of Colorado Cancer Center reports this week in the journal Cancer that 24 of 920 patients (3 percent) with advanced - stage lung cancer had mutations in the gene HLung Cancer Mutation Consortium at the University of Colorado Cancer Center reports this week in the journal Cancer that 24 of 920 patients (3 percent) with advanced - stage lung cancer had mutations in the geneCancer Mutation Consortium at the University of Colorado Cancer Center reports this week in the journal Cancer that 24 of 920 patients (3 percent) with advanced - stage lung cancer had mutations in the geneCancer Center reports this week in the journal Cancer that 24 of 920 patients (3 percent) with advanced - stage lung cancer had mutations in the geneCancer that 24 of 920 patients (3 percent) with advanced - stage lung cancer had mutations in the gene Hlung cancer had mutations in the genecancer had mutations in the gene HER2.

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses osimertinib (Tagrisso) for the treatment of patients with non — small cell lung cCancer Center, discusses osimertinib (Tagrisso) for the treatment of patients with non — small cell lung cancercancer.